Literature DB >> 24973442

Antigen-pulsed bone marrow-derived and pulmonary dendritic cells promote Th2 cell responses and immunopathology in lungs during the pathogenesis of murine Mycoplasma pneumonia.

Nicole A Dobbs1, Xia Zhou2, Mark Pulse3, Lisa M Hodge3, Trenton R Schoeb4, Jerry W Simecka5.   

Abstract

Mycoplasmas are a common cause of pneumonia in humans and animals, and attempts to create vaccines have not only failed to generate protective host responses, but they have exacerbated the disease. Mycoplasma pulmonis causes a chronic inflammatory lung disease resulting from a persistent infection, similar to other mycoplasma respiratory diseases. Using this model, Th1 subsets promote resistance to mycoplasma disease and infection, whereas Th2 responses contribute to immunopathology. The purpose of the present study was to evaluate the capacity of cytokine-differentiated dendritic cell (DC) populations to influence the generation of protective and/or pathologic immune responses during M. pulmonis respiratory disease in BALB/c mice. We hypothesized that intratracheal inoculation of mycoplasma Ag-pulsed bone marrow-derived DCs could result in the generation of protective T cell responses during mycoplasma infection. However, intratracheal inoculation (priming) of mice with Ag-pulsed DCs resulted in enhanced pathology in the recipient mice when challenged with mycoplasma. Inoculation of immunodeficient SCID mice with Ag-pulsed DCs demonstrated that this effect was dependent on lymphocyte responses. Similar results were observed when mice were primed with Ag-pulsed pulmonary, but not splenic, DCs. Lymphocytes generated in uninfected mice after the transfer of either Ag-pulsed bone marrow-derived DCs or pulmonary DCs were shown to be IL-13(+) Th2 cells, known to be associated with immunopathology. Thus, resident pulmonary DCs most likely promote the development of immunopathology in mycoplasma disease through the generation of mycoplasma-specific Th2 responses. Vaccination strategies that disrupt or bypass this process could potentially result in a more effective vaccination.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24973442      PMCID: PMC4129457          DOI: 10.4049/jimmunol.1301772

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  72 in total

1.  The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1.

Authors:  A Moore; L McCarthy; K H Mills
Journal:  Vaccine       Date:  1999-06-04       Impact factor: 3.641

2.  Depletion of CD8+ T cells exacerbates CD4+ Th cell-associated inflammatory lesions during murine mycoplasma respiratory disease.

Authors:  Harlan P Jones; Leslie Tabor; Xiangle Sun; Matthew D Woolard; Jerry W Simecka
Journal:  J Immunol       Date:  2002-04-01       Impact factor: 5.422

Review 3.  T lymphocyte responses are critical determinants in the pathogenesis and resistance to mycoplasma respiratory disease.

Authors:  Harlan P Jones; Jerry W Simecka
Journal:  Front Biosci       Date:  2003-05-01

4.  Transfer of antigen-pulsed dendritic cells induces specific T-Cell proliferation and a therapeutic effect against long-term Helicobacter pylori infection in mice.

Authors:  Satoshi Otsu; Kazuyo Gotoh; Tetsu Yamashiro; Junpei Yamagata; Kouichirou Shin; Toshio Fujioka; Akira Nishizono
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

5.  Standardisation of glutaraldehyde-modified tyrosine-adsorbed tree pollen vaccines containing the Th1-inducing adjuvant, monophosphoryl lipid A (MPL).

Authors:  M Hopkins; B G Lees; D G Richardson; S R Woroniecki; A W Wheeler
Journal:  Allergol Immunopathol (Madr)       Date:  2001 Nov-Dec       Impact factor: 1.667

6.  Chronic respiratory mycoplasmosis in C3H/HeN and C57BL/6N mice: lesion severity and antibody response.

Authors:  S C Cartner; J W Simecka; J R Lindsey; G H Cassell; J K Davis
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

7.  Derrick Edward Award Lecture. The pathogenic potential of mycoplasmas: Mycoplasma pulmonis as a model.

Authors:  G H Cassell
Journal:  Rev Infect Dis       Date:  1982 May-Jun

8.  Long-term epidemiology of infections with Mycoplasma pneumoniae.

Authors:  H M Foy; G E Kenny; M K Cooney; I D Allan
Journal:  J Infect Dis       Date:  1979-06       Impact factor: 5.226

9.  Characterization of murine dendritic cell line JAWS II and primary bone marrow-derived dendritic cells in Chlamydia muridarum antigen presentation and induction of protective immunity.

Authors:  Xiaozhou Jiang; Caixia Shen; Jose Rey-Ladino; Hong Yu; Robert C Brunham
Journal:  Infect Immun       Date:  2008-03-24       Impact factor: 3.441

10.  Evaluation by scoring and computerized morphometry of lesions of early Mycoplasma pulmonis infection and ammonia exposure in F344/N rats.

Authors:  D M Pinson; T R Schoeb; J R Lindsey; J K Davis
Journal:  Vet Pathol       Date:  1986-09       Impact factor: 2.221

View more
  3 in total

Review 1.  Advances in immunotherapy delivery from implantable and injectable biomaterials.

Authors:  David G Leach; Simon Young; Jeffrey D Hartgerink
Journal:  Acta Biomater       Date:  2019-02-13       Impact factor: 8.947

2.  Interleukin-17A Exacerbates Disease Severity in BALB/c Mice Susceptible to Lung Infection with Mycoplasma pulmonis.

Authors:  Maximillion T Mize; Xiangle L Sun; Jerry W Simecka
Journal:  Infect Immun       Date:  2018-08-22       Impact factor: 3.441

Review 3.  Interactions of Bacteriophages and Bacteria at the Airway Mucosa: New Insights Into the Pathophysiology of Asthma.

Authors:  Panagiota Tzani-Tzanopoulou; Dimitrios Skliros; Spyridon Megremis; Paraskevi Xepapadaki; Evangelos Andreakos; Nina Chanishvili; Emmanouil Flemetakis; Grigoris Kaltsas; Styliani Taka; Evangelia Lebessi; Anastassios Doudoulakakis; Nikolaos G Papadopoulos
Journal:  Front Allergy       Date:  2021-01-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.